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Background {#Sec2}
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Orthodontic tooth movement (OTM) is considered an epiphenomenon of the gene expression of the periodontal ligament (PDL) and neighboring cells resulting from a series of orchestrated cellular and molecular events in alveolar bone and periodontal tissue initiated by the application of orthodontic force \[[@CR1]\]. A chemical cascade that mediates the transmission of signals from extracellular matrix leading to genetic modulation is interceded by the release of mediators in paracrine environment. These signals are responsible for a change in the cytoskeletal structure, leading to alteration of nuclear protein matrix and eventually gene activation or suppression \[[@CR2],[@CR3]\]. These events initiate the process of bone remodeling, leading to effective tooth movement. The biochemical mediators released sequentially at multiple stages during orchestration of tooth movement can be detected in gingival crevicular fluid (GCF). GCF is a unique biological exudate that has been found as a convenient medium to study these mediators with reasonable sensitivity. GCF can be collected noninvasively \[[@CR4]\] with specifically designed filter paper or a micropipette (1 to 10 μl) or through magnetic beads placed in gingival crevice. GCF once collected may be cryopreserved or directly sent for chemical analysis. GCF can also be collected repeatedly at various stages of orthodontic treatment and therefore provides useful insight to biological events over the entire duration of observation.

Clinically demonstrable success of OTM is associated with expression of numerous regulatory molecules, of which cytokines have been most widely documented. Cytokines are low-molecular weight proteins (mw \< 25 kDa) released in autocrine or paracrine environment in response to local signals like application of stress \[[@CR5]\] and are involved in normal physiological bone turnover and remodeling \[[@CR6]-[@CR8]\]. Cytokine biology as a retort to forces applied for OTM is difficult to comprehend due to sheer number and complexity of these factors exhibiting redundancy as well as pleiotropy \[[@CR9]\]. Although cytokines have been extensively evaluated in GCF as quantitative biochemical indicators of inflammatory periodontal status \[[@CR10]\], there has been an increasing interest on understanding their contributions as mediators of OTM owing to their role in bone and tissue remodeling. Among these cytokines, interleukins (ILs) (IL-1α, IL-1β, IL-1RA, IL-8, IL-2, IL-6, and IL-15), tumor necrosis factors (TNFs), interferons (IFNs), growth factors (GFs), and colony-stimulating factors (CSFs) have been extensively studied in relation to OTM.

The secretion of these mediators in the local environment by cells activated on application of orthodontic force varies according to the force levels and functional state of available target cells. The rate of OTM depends on recruitment of mature osteoclasts and precursors, osteoclast differentiation and number of functional osteoclasts at the bone-PDL interface, where bone resorption is considered a rate-limiting step \[[@CR11]\]. The earliest identified marker of bone resorption is IL-1β, closely followed by prostaglandin E2 (PGE2), nitric oxide, IL-6, and other inflammatory cytokines \[[@CR12]\]. TNF is also believed to have synergistic effects with IL-1 \[[@CR13]\]. Osteoclast differentiation and activation is mediated by the binding of receptor activator of nuclear factor kappa-B to its ligand expressed by osteoblasts and PDL cells (RANK and RANKL, respectively) \[[@CR11],[@CR14]-[@CR16]\]. This interaction and osteoclast activity is prevented by a decoy receptor for RANKL called osteoprotegerin (OPG) \[[@CR17]\]. Thus, the relative balance between RANK-RANKL and OPG may be critical to the magnitude and rate of OTM.

The first experimental evidence supporting role of cytokines in OTM was documented in periodontal tissues of cat canine teeth where IL-1α and IL-1β were identified after the application of a tipping force \[[@CR18]\]. One of the earliest noninvasive studies on IL-1β in GCF was done by Grieve et al. \[[@CR19]\] where significant elevations from baseline in IL-1β and PGE levels supported initial release of proinflammatory mediators on application of orthodontic forces, followed by a decrease in 7 days (d). Since then, numerous studies in humans have focused on alterations in IL-1β levels in GCF in an attempt to understand the underlying inflammatory process during OTM. The studies have now diversified to include other interleukins like IL-1α, IL-2, IL-6, IL-8, and receptor antagonist IL-1RA. More recently, the presence of other mediators including TNF-α, TGF-β, leptin, RANK/RANKL, and OPG have also been explored in OTM.

This systematic review aims to determine effect of orthodontic forces on levels of markers of inflammation namely cytokines, chemokines, receptors and their antagonists, which have been widely documented in GCF. The present study looks into literature to generate evidence on the role of these mediators in relation to the force levels, applied mechanics, age, sex and pain intensity during orthodontic treatment. This systematic review provides insights into possible biomarkers for tooth movement and their potential contributions to modulating orthodontic bone turnover that could prove useful in designing future approaches to modulating OTM.

Material and methods {#Sec3}
====================

This review was registered in PROSPERO on 3 June, 2014 (registration number CRD42014009302). The systematic review was conducted strictly adhering to guidelines suggested by PROSPERO. A search strategy was finalized utilizing MESH terms, Boolean terminology, and free text terms (Additional file [1](#MOESM1){ref-type="media"}: Annexure 1). This search strategy was applied to key databases PubMed, Scopus, and Embase in April 2014 by two reviewers PK and NM which followed a cross check by third reviewer OPK. Apart from that, hand search of journals was performed for article retrieval. Segregation of articles to be considered for review was based on stringent inclusion and exclusion criteria. Seventy-seven articles in PubMed, 637 in Scopus, 51 in Embase, and 3 from hand searching were retrieved (Figure [1](#Fig1){ref-type="fig"}). Duplicates were removed before final screening of articles for inclusion in the review. The titles and abstracts of these manuscripts were studied, considering exclusion and inclusion criteria specific to each database (Figure [1](#Fig1){ref-type="fig"}). The relevant articles were obtained. These were PubMed - 41, Scopus - 17, Embase - 2 and hand searched - 3. Further, a few articles had to be excluded for non-availability of full text. These were PubMed (N = 4), Scopus (N = 15), and Embase (N = 1). Further, four articles had to be excluded since full text revealed no mention of orthodontic force (N = 1) or study was not performed in crevicular fluid (N = 3). A consensus has arrived among reviewers for final inclusion of 39 articles comprising of 33 articles from PubMed, 2 from Scopus, 1 from Embase, and 3 from hand search (Figure [1](#Fig1){ref-type="fig"}).Table 1**Participant characteristicsRef no.SxM/FAgeMediatorsIndex TCont TSite spRndMalN drug HN bone LsN Ging inflmPD (\<2 mm)**22162 M, 14 F18 to 24 yIL-1βMx and Md CMd R or L CDYClass I biMxYNMYNM232211 M, 11 F14.4 + \_1.1 yLeptinMx CContr CDNMx 1st PM Extr csYYYY243321 M, 12 F10.8 to 30.9 yIL-1β, IL-1RAMx CIP Md C/Aj TDyMx 1st PM Extr csNMNMNMNM25127 F, 5 M13 to 17 yOPGMx CContr CDNMx 1st PM Extr csYYYY2695 M, 4 M10 to 18 yIL-1β, βG1st Mo, 1st PM, CINMMP and MBNRME csNMNMNMNM2712 SD (6) LD (6)SD: 3 M, 3 F\
LD-NMSD: 11 to 18 y\
LD: 19 to 27 yIL-1β, −6, IL-8, TNF-αMx 1st PMAnt TDBNMx 2nd PM Extr csYYYY28104 M, 6 FNMTNF-αCNMDNMx 1st PM Extr csYYYY29189 M, 9 F16 to 19 yIL-1β, −TNF-αMx CNMM and DN1st PM Extr csYYYY3030:15 J/15 AJ: 7 M, 9 F\
A: 6 M, 9 FJ: 15.1 ± 2.8 yRANKL, OPG1 Mx CContr and ant CDNMx 1st PM Extr csYYYYA: 31 ± 3.6 y31156 M, 9 F15 to 19 yIL-2, IL-6, IL-8Mx CNMM and DN1st PM Extr csYYYY32104 M, 6 FM −14.5 yRANKL, OPGMx CContr and opposing CDNMx 1st PM Extr csYYYYF 15.4 y331810 M, 8 F8.9 to 13.8 yIL-1β, SP, PGE21st Mx/Md MAnt L or R 1st MDB and DPNCrowding in 1 or both jawsYYYY3493 M, 6 FM: 21.3 ± 2.8 yIL-1β, SPMx CContr CDNMx 1st PM Extr csYYYYF: 23.1 ± 2.4 y35103 M, 7 F10 y 5 m to 30 y 11 mIL-1β, IL-1RAR and L Mx CMd. R CM and DYMx 1st PM Extr csNMNMNMNM3610NM15 to 17 yIL-8Mx and Md CNMM and D1st PM Extr csYYYY37102 M, 8 F18.4 to 22.5 yIL-1β, PGE2Mx C (E1), Contr Mx C (E2)Ant Md CDNAll 1st PM Extr csYYYY388443 J (M)J: 11 ± 0.7 yPGE-2, IL-6, GMCSFMx LIContr LIM and DBNLabial tipping reqdYYYY41 A (M)A: −24 ± 1.6 y3995 M, 4 F10 to 18 yIL-1β βG1st Mo, 1st PM, CINMMP and MBNRME csYYYY4072 M, 5 F12 y 3 m to 16 y 3 mIL-1β, IL-1RA, AIMx CMd CM and DNMAll 1st PM ExtrYNMYNM41123 M, 9 F14.4 ± 0.9 yTGF-βCAnt C/Contr CDNMAll 1st PM ExtrYYYY42123 M, 9 F14.4 ± 0.9 yIL-1β, IL-6, TNF-α, EGF, β2-μGCAnt C/Contr CDNMAll 1st PM ExtrYYYY19105 M, 5 FM: 24.6 ± 1.5 y F: 27.8 ± 3.9 yIL-1β, PGEMx LI, Mx 1st PMContr TMBNBuccal/labial OTMYYYY435023 M, 27 F13 to 20 yIL-1β, TNF-α, NOMx I, Mx CNMM and DNMNon ExtrYNMYY44105 M, 5 F12 to 16 yRANKL, OPG1st PM (quad 1)1st PM (quad 2)DNM2nd Mx PM ExtrYNMYNM45227 M, 15 F19 to 29 yHSP70, RANKLMx CContr CNMMx 1st PM ExtrYNMYNM46126 M, 6 F11 to 15 yMMP-8, IL-1β1st M, CI, CNMMNMNMYYYY4721NM12 to 20 yGM-CSF, IF-ϒ, IL-1β, IL-2, IL-4, IL-5, IL-6, IL-8, IL-10 and TNFα, MMP-9, TIMP-1 and 2, RANKL, OPGMx C2nd MMB and DPNMMx 1st PM ExtrYYYY48105 M, 5 F22 to 29 yRANK, OPG, OPN, TGF-β11st MContr MExp T: MB and DB Cont T: MB and MLYNMYNMYY49143 M, 11 F12 to 28 yMMP-3, MMP-9, MMP-13, MIP-1β, MCP-1, RANTESMx CNMM and DNMMx 1st PM ExtrYNMNMNM50188 M, 10 F8.9 to 13.8 yIL-1β, SP, PGE21st MContr MM and DNMCrowding in Mx and MdYYYY5110NM16.3 ± 2.5 yIL-1βMx CMd CDBNMClass II, all 1st PM ExtrYYYY52168 M, 8 F16.6 ± 2.4 yIL-2, IL-6, IL-8Mx CMx 2nd PMDBNMMx 1st PM ExtrYYYY5320C: 3 M, 7 F\
EX:5M,5 F18 to 45 yCCL-2 (MCP1), CCL-3, CCL-5 (RANTES), IL-8 (CXCL8), IL-1α, IL-1β, IL-6, TNF-αMx CContr CDBYClass II Div 1 Mal With 1st PM ExtrYYYY54168 M, 8 F16.6 ± 2.4 yTNF-αMx CMx 2nd PMDBNMMx 1st PM ExtrYYYY55179 M, 8 F16 to 20 yTNF-α, IL-1β, IL-8Mx CNMM and DNMAll 1st PM ExtrYYYY56105 M, 5 F15 y ± 3 y 8 mIL-1β, IL-1RAMx CMd C/Aj tDNMAll 1st PM ExtrNMNMNMNM572010 ado (3 M, 7 F), 10 A (4 M, 6 F)Ado: 14.4 ± 1.43 y\
A: −28.5 ± 7.83 yRANKL, OPG, IL-1, IL-1RA, MMP-9Mx IMd ILabNMNon Extr, 3 to 6 mm I crowdingNNYN5824 HG-14 NHG-1010 M, 14 F\
HG: 6 M, 8 F14.66 ± 1.1 yIL-2, IL-4, IL-6, IL-8, IL-10, GM-CSF, IFN-γ, TNFα, MCP-1, IP-10Mx 1st M and Mx 1st PMNMMB and DBNNon extr csYNMYY5994 M, 5 F17.5 to 18.9 yOPG, RANKLMx CNMM and DNMAll 4 ExtrYYYY*Ref No.* reference number, *S* sample, *M/F* male/female, *med* mediator, *T* tooth, *sp* specification, *Rnd* randomization, *Mal* malocclusion, *HS* hand searched, *P* PubMed, *S* Scopus, *E* Embase, *N* no, *Y* yes, *Mx* maxilla, *Md* mandible, *H* history, *Ls* loss, *Ging* gingival, *Inflm* inflammation, *PD* probing depth, *NM* not mentioned, *m* month, *d* day, *wk* week, *h* hour, *R* right, *L* left, *C* canine, *PM* premolar, *Mo* molar, *CI* central incisor, *Ant* antagonistic, *Contr* contralateral, *IP* interproximal, *oppos* opposing, *Exp* experimental tooth, *Cont* control tooth, *Aj* adjacent, *E1* experimental site 1, *E2* experimental site 2, *Extr* extraction, *M* mesial, *D* distal, *Retr* retraction, *y* year, *cs* cases, *IL* interleukin, *NO* nitric oxide, *RANKL* receptor activator of NFкB ligand, *β2-μG* β2 microglobulin, *TNF* tumor necrosis factor, *TGF* transforming growth factor, *EGF* epidermal growth factor, *SP* substance P, *PGE* prostaglandin, *HSP* heat shock protein, *IFN* Interferon, *MMP* matrix metalloproteinase, TIMP tissue inhibitor of metalloproteinases, *MCP* monocyte chemoattractant protein, *MIP* macrophage inflammatory process, *RANTES* regulated on activation normal T cells expressed and secreted, *GM-CSF* granulocyte-macrophage colony-stimulating factor, *reqd* required, *quad* quadrant, *OTM* orthodontic tooth movement, *Lab* labial surface, *ado* adolescent, *J* juveniles, *A* Adults.Table 2**Study characteristicsRef no.FT/O FMechMech/O appliReactTot DuNo. of obsTime obsBasBas (same as cont)**22.50 and 150 gCont FRetr- seNi-Ti spgN2 m60, 1, 24 h, 1 wk, 1 m, 2 m0N23.250 gIntrrup FRetr- seE-chainNM168 h40, 1 h, 24 h, 168 h0N244, 13, 26, 52, or 78 kPaCont FRetr- seVert loop act. with Ni-Ti spgN84 d9 to 100, 1, 3, ±7, 14, 28, 42, 56, 70, 84 d0N25150 gCont FRetr- seNi-Ti spgN3 m6before act 0, after act 1 h, 24 h, 168 h, 1 m, 3 m0N26NMInterm FMx expansHyrax screwY81 d100, 14, 25, 32, 33, 39, 46, 53, 60, 81 d14 dY27SD-NM LD-50 cNSD - intrrup F LD - cont FSD - space gaining LD - Retr- seSD-E - separt LD - Ni-Ti spgNSD - 24 h LD - 4 mSD - 2 LD - 5SD - 0 h, 24 h LD - 0, T1, 1 m, 2 m, 3 m0N28HG - RDG-NMHG - cont F RDG - heavy Intrrup FRetr- seHG - hybrid retract RDG - C distalizerHG-N RDG-Y1 wk4Before act (0), after act 1 h, 24 h, 1 wk0Y29Level-NSCont FLevel Retr- se0.014" NiTi wire\
Sentalloy c.c. spgN6 m 21 d7Level - 0, 7 d, 21 d, 3 m\
After 6 m Retr - 6 m (0), 7 d, 21 dLevel - 0\
Retr - 6 m-0YRetr - 150 gCont F30250 gIntrrup FRetr- seE-chainNM168 h40, 1, 24, 168 h0N31Level-NSCont FLevel Retr- se0.014" NiTi wire\
Sentalloy c.c. spgNM6 m 21 d6Level - 0, 7 d, 21 d\
After 6 m Retr - 6 m (0), 7 d, 21 dLevel - 0\
Retr - 6 m-0YRetr - 150 gCont F32250 gIntrrup FRetr- seE-chainN7 d40, 1, 24, 168 h0N33NMIntrrup FSpace gainingE - separtN14 d5−7 d, 0 d, 1 h, 1 d, 7 d0N34250 gIntrrup FRetr- seE-chainN168 h80, 1, 4, 8, 24, 72, 120, 168 h0N3560, 18, 120, 240 gCont FRetr- seVert loop act. with Ni-Ti spgN112 d11−28, −14, 0, 1, 3, 14, 28, 42, 56, 70, 84 d0N36Mx C - 115 gCont FRetr- seRicketts seg archN30 d60, 1 h, 24 h, 6 d, 10 d, 30 d0YMd C - 90 g37E1: 100 gE1: ContRetrE1: NiTi spgE1: N3 wk100, 1 h, 24 h, 1 wk, repeat twice0NE2: NME2: IntrrupE2: screw attached retractorE2: 23870 cNContTippingbu/la offsetN24 h20, 24 h0N39NMInterm FMx expansHyrax screwY81 d110, 14, 18, 25, 32, 33, 39, 46, 53, 60, 81 d0Y4013 to 4 kPaContRetrV loop act by spgN84 d90, 1, 3 d, 14 d intervals until 84 d0N412 to 2.5 NIntrrupRetrE-chainN7 d40, 1, 24, 168 h0N42250 gIntrrupRetrE-chainN7 d40, 1, 24, 168 h0N19100 gContLabial tippingLa offset in NiTi wireN7 d50, 1, 24, 48, 168 h0N43NMNMNMAlignmentNM6 m30, 1 m, 6 m0N44150 gContRetrNiTi spgN45 d60, 2, 4, 7, 30, 45 d0N45130 gIntrrupRetrE-chainN24 h20, 24 h0N46NMNMNMBracket placementN3 m40, 24 h, 1 wk, 3 m0Y47100 gContRetrNiTi c.c. spgN42 d4−10 wk, 0, 4 h, 7 d, 42 d0N48NMIntrrupSpace gainElastic separtN7 d30, 24 h, 7 d0N49150 gContRetrV - loop and NiTi c.c. spgN87 d7−7 d, 0, 1 h, 24 h, 14, 21, 80 d0Y50NMIntrrupSpace ginElastic separtN14 d6−7 d, 0, 1 min, 1 h, 1 d, 7 d0N51120 gContRetrNiTi c.c. spgN21 d61 h, 24 h, 48 h, 168 h, 14 d, 21 d1 hN52150 gContRetrSentalloy c.c. spgN3 m70, 1, 24, 48 h, 7 d, 21 d, 3 m0N53100 gCont FRetr- seNi-Ti c.c. spgN28 d40, 1 d, 7 d, 28 d0Y54150 gContRetrSentalloy c.c. spgN3 m70, 1, 24, 48 h, 7 d, 21 d, 3 m0N55NMContAlignment0.014 NiTi wireN7 d80, 1, 2, 3, 4, 5, 6, 7 d0Y5613, 26, 52 kPaContRetrV loop act by spgN84 d90, 1, 3 d, 14 d intervals until 84 d0N57NMContAlignment0.014 - NiTi, 0.016 × 0.022 NiTi, 0.019 × 0.025 NiTiN20 wk60, 3 wk, 6 wk, 12 wk, 2 wk0N58NMHG: band intrrup F Bond - Cont F NHG - Cont FLevel0.014 - in NiTi wire 0.016 × 0.022-in s.s.N70 wkHG: band-3 HG; bond-2 NHG-2HG: band - 18, 0, 52 wkHG: band - 18 wkYHG: bond - 0, 52 wkBond - 0 wkNHG - 0, 52 wkNHG - 0 wk59200 gContRetrSentalloy c.c. spgN1 m50,1 h, 24 h, 168 h, 1 m0Y*Ref No.* reference number, *F* force, *T/O* type of, *Mech* mechanics, *Mech/O* mechanics of, *appli* appliance, *React* reactivation, *Tot* total, *Du* duration, *N* number, *obs* observation, *Bas* baseline, *min* minutes, *g* grams, *Intrrup* interrupted, *Cont* continuous, *interm* intermittent, *Retr* retraction, *se* segmented, *spg* spring, *E-chain* elastomeric chain, *NiTi* nitinol, cont control, *NM* not mentioned, *y* year, *d* day, *m* month, *h* hour, *Level* leveling, *separt* separator, *act* activated, *HG* headgear, *NHG* non-headgear, *bu* buccal, *la* labial, *HG* hybrid retract, *RDG* rapid canine distalizer.Table 3**Oral hygiene regimen and assessment of gingival healthRef no.Mu wshFreq/O Mu wsh/dOral prophy (pre t/t)Oral prophy (every obser pt)Asses for ging and perio inflam (pre t/t)At every obser pt**22ChlorhexTwiceNMNMYY23NNAYYYAt 0 and 168 h24NMNMYYYY25NMNAYYNN26ChlorhexTwiceYNMYY27ChlorhexTwiceYYYY28NMNANMNMYNM29NMNANMNMNMNM30NMNAYYYY31NMNANMNMNMNM32NMNAYYYY33ChlorhexTwiceYYYY34NMNAYYYY35ChlorhexTwiceYYYY36NMNMYYYY37NMNMNMNMYY38NMNMYYNMNM39ChlorhexTwiceYNMYY40ChlorhexTwiceYYYY41NMNMNMNMYY42NMNMNMNMYY19ChlorhexNMNMNMY43NMNMYYYY44ChlorhexTwiceYYYY45NMNMYYNMNM46NMNMYY (6 wk, 3 m)YY47NMNMNMNMYY48NMNMYYYY49ChlorhexTwiceYYNMNM50NMNMYNYY51NMNMNMNMNMNM52NMNMYYYNM53NMNMYYYNM54NMNMYYYNM55NMNMNMNMNMNM56ChlorhexTwiceYYYY57NMYNMNMNM58NMNAYNMYY59NMYYYY*Ref No.* reference number, *Mu* mouth, *wsh* wash, *Freq/O* frequency of, *d* day, *prophy* prophylaxis, *t/t* treatment, *obser* observation, *pt* point, *Asses* assessment, *ging* gingival, *perio* periodontal, *inflam* inflammation, *chlorhex* chlorhexidine, *Y* yes, *NM* not mentioned, *N* no, *h* hour.Table 4**GCF characteristicsRef no.TimeTempHumdSite spInser (in mm)Rep measI/O measMeth/O collDu/O measTemp of stoMeth/O measAnal methProt conc**22NMNMNMD1 mm290 sPP30 s−80°CPT8000ELISApg/mg23YNMNMD1 mm460 sPP30 s−80°CPT8000ELISApg/ml24NMNMNMDNM2NMNMNMNMNMELISANM25NMNMNMD1 mmNNAPP30 s−80°CPT8000ELISApg/μl26NMYYMNMNNAPP30 sNMPT6000ELISApg/30 s27NMNMNMDB1 mmNNAPP30 s−20°CPT8000MB-IApg/μl28YNMNMD1 mm460 sPP30 s−80°CElec scaleELISApg/μl29YNMNMM and D1 mmNNAPP30 s−20°CPT8000IApg30NMNMNMD1 mm260 sPP60 s−30°CPT8000ELISApg/μl31YNMNMM and DNMNNAPP30 s−20°CPT8000IApg32NMNMNMD1 mm160 sPP60 s−30°CPT8000ELISApg/μl33NMNMNMDB and DP1 mmNMNADuFM20 s−70°CNMELISApg/20-s samp34NMNMNMD1 mm2NMPP60 s−30°CPT8000ELISApg/μg35NMNMNMM and D1 mm160 sPP30 s−70°CNMELISAmg/l - tot prot, IL-1-ng/g IL-1RA- μg/g36NMNMNMM and D1 mm160 sPP30 s−70°CElect scaleELISApg/ml37YYYD1 mm41 minPP30 s−70°CNMELISApg/μg38NMYNMMB and DB1 mmNNPP30 s−80°CPT6000RIApg/μl39NMYYMNMNNAPP30 sNMPT6000ELISApg/30-s GCF40NMNMNMM and D1 mm11 minPP30 s−70°CNMELISATot prot - mg/l, IL-1β (ng/g), IL-1RA (μg/g)41NMNMNMD1 mm11 minPP30 s−30°CPTELISA, EP, WBpg/μg42NMNMNMD1 mm11 minPP30 s−30°CPTELISApg/μg19YYyMB1 mmNNPP30 s−80°CPT6000RIApg43NMNMNMM and DNMNMNMPP30 sNMPT8000ELISANM44NMNMNMDNMNNPP30 s−80°CPT8000ELISApg/μl45NMNMNMD2 mm12 minPP1 min−20°CNMELISA, WB, SDS-PAGENM46NMNMNMMNMNNFP3 min−30°CNMELISAIL-1β; pg/ml, MMP-8: ng/ml47NMNMNMMB and DPNMNNPP30 sNMPT8000LMATpg/ml48NMNMNMExpT: MB and DB\
Cont T: MB and ML1 mmNNPP30 sNMPT8000ELISACyt conc - pg/μl\
Tot prot (pg)49NMNMNMM and D1 mmNNPPNM−80°CPT8000MB-IApg/site50NMNMNMMB and DB1 mmNNFM20 s−70°CNMELISApg/20 s51YYYDBNMNNFP3 min−70°CNMELISApg/μl52YNMNMDBNM11 minPP30 s−20°CPT8000ELISApg/μl53YNMNMDB1 mm0NAFP10 sNMPT8000CPApg/μl54YNMNMDBNM11 minPP30 s−20°CPT8000IApg/μl55YNMNMNM1 mmNNPP30 s−20°CPT8000IApg56NMNMNMD1 mm11 minPP30 s−70°CNMELISATot prot - mg/l, IL-1β (ng/g), IL-1RA (μg/g)57NMNMNMDL1 mmNNPP30 s−80°CNMQAKpg/ml58NMNMNMMB and DBNM2NAPP30 s−70°CPT6000BHCApg/ml59NMNMNMM and D1 mm11 minPP30 s−70°CPrecisa 62 AELISApmol/l*Ref No.* reference number, *Humd* humidity, *sp* specification, *Inser* insertion, *MB* mesio-buccal, *ML* mesio-lingual, *DP* disto-palatal sites, *DB* disto-buccal sites, *M* mesial, *D* distal, *NM* not mentioned, *N* no, Y yes, *PP* periopaper, *PT* periotron, *FP* filter paper strips, *FM* Durapore filter membrane, *WB* Western blot, *ELISA* enzyme linked immune sorbent assay, *SDS-PAGE* sodium-dodecyl sulfate polyacrylamide gel electrophoresis, *RIA* radio-IA, *I/O* interval of, *Meth/O* method of, *coll* collection, *meas* measurement, *Du/O* duration of, *Temp* temperature, *sto* storage, *Anal* analysis, *Prot* protein, *conc* concentration, *pg* picogram, *mg* microgram, *ml* milliliter, *μl* microliter, *GCF* gingival crevicular fluid, *tot* total, *g* gram, *ng* nanogram, *s* seconds, *min* minutes, °C degree Celsius, *elect* electronic, *IA* immunoassay, *EP* electrophoresis, *sP* spectrophotometry, *Ar* array, *A* assay, *MB* multiplex bead, *LMAT* Luminex multianalyte technology, *BHCA* Bio-Plex human cytokine assay, *CPA* custom protein array, *QAK* Quantibody Ar kit, *DuFM* Durapore filter membrane.Table 5**Result characteristicsRef no.MediatorsStats analy appldConfdDrop outsUp/down regPkSec outcmrStat sign readings**22.IL-1βANOVA and Friedman and paired *t*YNMInc24 h, 2 m1. Mean tot prot conc - 12 mg/mlC mov with less pain and inflam with 50 g than with 150 g of FInc at 24 h and 2 m in 150 g F compd to cont2. VAS score of 150 g \> 50 g at 24 h23.LeptinWilcoxon, FriedmanNMNMDec168 hNMNMb/w bas and 168 h in exp T24IL-1β, IL-1RAANCOVAYYFluctNMFor same stress and grw status, max diff in speed were 4.2:1 for 13 kPa in growers and 4.8:1 for 26 kPa in Nn-growersHigher speeds of T move sign assoc with gen type 2 at IL-1β (+3,954), higher AI, and lower IL-1RA in GCFNM25OPGShapiro Wilk's Normality, Wilcoxon, Friedman, ZNMNMDecNMNMNMDec at 1 h, 24 h, 168 h, 1 m, 3 m compd with bas26IL-1β, βG1-tailed paired Student *t*YNMIncM-010 PM-07 CI-08βG sign inc for M - 07 to 010 PM-07,08,010 CI - 06, 07, 010 and dec at O2 for M, PM, CIStronger F cause higher levels of both IL-1β and βGIL-1β sign inc for M - O5 to O10 for PM-O6 to 010.\
For CI - 04, 06, 07, 09, 010 and dec at O2 for M, PM, CI27IL-1β, IL-6, IL-8, TNF-αMann-Whitney, Kruskal-WallisYNMIncSD - 24 h LD - T1NMNMIn SD IL-1β, IL-8, TNF-α inc, In LD inc of IL-8 at T128TNF-αIntergrp - Mann-Whitney U\
Intragrp - Wilcoxon signed rankNMNMInc24 hPI, PD, BOP sign higher in HG GCF vol at 1 h and 24 h in the RDG \> HGNMHG - a stat sign dec at 1 wk compd to 24 h.\
RDG - inc at 1 h stat sign compd to initial value. Inc in RDG at 1 h \> HG29IL-1β,-TNF-α1-way paired *t*, Mann-Whitney UNMNMInc7 d, 21 dGCF vol inc on 7 d and 21 d of level and retrNMTNF --α diff b/w 3 m (level) and 6 m (bf retr)30RANKL, OPG3-way analysis of variance Tukey's honest sign diffYNMRANKL- Inc OPG- Dec24 havg amt of TM for J \> A after 168 h mean vol of GCF in A sign lower than JGCF vol correl with inflam stateRANKL at 24 h - sign inc levels both in J & A. RANKL and OPG in A \< J OPG at 24 h sign dec levels both in J & A. RANKL/OPG for exp T sign \> cont after 24 h RANKL/OPG in A \< J31IL-2, 6, 81-way paired *t* Mann-Whitney UNMNMIL-2-incIL-2 - 7 d, 21 d of level IL-8 - 7 d of level and 7 d, 21 d of retrGCF vol greater on 7 d and 21 d of level and retrNMIL-8 stat sign dec on 7 d of levelIL-6-N changeIL-8-dec32RANKL, OPGMann-Whitney UNMNMRANKL - inc OPG - dec24 h*In vitro* compres F for 3, 6, 9, 12, 24, 48 h, RANKL was sign inc in stress (+) grpN sign diff in mean vol of GCF at 24 h b/w exp T and cont TMean RANKL values after 24 h in Exp \> cont-mean OPG values after 24 h in Exp \< cont33IL-1β, SP, PGE2Paired *t* multiple linear regression analysisYNMInc1 dVAS inc sign 1 h and 24 h after insert of sepr and returned to bas after 7 d SP and PGE2 sign higher at 1 d and 7 dNMIL-1β of exp \> cont at 1 h, 1 d, 7 d34SP, IL-1βMann-Whitney U Spearman's signed rankNMNMIncNMAvg amt of TM was 1.5 ± 0.4 mm over 168 h-N sign diff in tot prot level at any of exp time periods mean SP levels inc after 8, 24, and 72 h in ExpN sign diff in mean GCF vol b/w exp and cont Tmean IL-1β levels inc after 8, 24, and 72 h in Exp35IL-1β, IL-1RAANCOVAYNMNM3 dInc lag phase with Mx C moved by 4, 13, and 26 kPa.\
By 52 kPa, distinct lag phase at 3 d, 14 dVt vs avg AI in GCF from D sites of Mx C showed a + ve relationship (R^2^ = 0.44)mean AI for C moved with 52 kPa sign \> all other mean AIs36IL-8Mann-Whitney U WilcoxonNMNMInc6 d at tension site, and 1st 24 h at pressure siteGCF vol greater at tension and pressure sites at 24 h and 30 dNMIL-8 at both sites inc at 1 h of F. B/w 24hand 6 d, inc at tension site. IL-8 incamong grps b/w 0 & 1 h stats sign37IL-1β, PGE2Intra-grp: ANOVA Intergrp: 1-way ANOVANMNMInc24 hPGE2 inc at 24 h \> BS in CF and IF. PGE2 inc in CF and IF at 24 h \> cont In CF,PGE2 \> cont at 168 h, then fall. In IF, PGE2 remain high for a wk.NMIL-1β inc at 24 h \> BS, max at 24 h after 1st act in IF.In IF, IL-1β inc 24 h after 1st reactivn \> contIn CF and IF, IL-1β inc at 24 h \> cont38PGE-2, IL-6, GMCSFPaired *t* (intragrp) independent *t* (J and A)NMNMInc24 hMedian GCF vol. in J \> A. In J and A PGE2 inc at 24 h \> BSNMInJ, IL-6, GMCSF inc at 24 h \> BS39IL-1β, βG1-tailed paired Student *t*YNMIncIL-1β - 81 d βG - 46 dβG - significantly dec 14 d after prophy. Exp \> cont at 46 dNMIL-1β significantly dec 14 d after prophy. Exp \> cont at 4 d, 33 to 81 d40IL-1β, IL-1RA, AILeast square regression Pearson product-moment Correl coefficientNMNMInc3 dC retr at 1.27 and 0.87 mm/m for 13 and 4 kPa of stress, resp+ve corr of velocity and AI from D \> M.IL-1β at M \> Cont (13 kPa) IL-1RA at D \> M and Cont (4 and 13 kPa)\
Tot prot at M and D \> Cont (4 and 13 kPa)41TGF-βStudent's *t*YNMInc24 hC retr was 1.1 at 0.1 mm/168 hNMTGF-β at exp site at 24 h \> bas, Cont42IL-1β, IL-6, TNF-α, EGF, β2-μGStudent's *t*YNMInc24 hβ-2 MG inc at 24 h \> BS or 1 hNMIntra-grp in Exp: IL-1β inc at 24 h \> bas, IL-6 inc at 24 h \> bas or 168 h, TNF-α inc at 24 h \> bas or 168 h, EGF inc at 24 h \> basβ-2 MG in exp at 24 h \> ant contIntergrp btw cont and exp: IL-1β inc in exp \> cont at 24 h, mean IL-6 in exp \> ant cont, TNF-α in exp at 24 h \> ant cont, EGF in exp at 24 h \> ant cont19IL-1β, PGE2-way analy of variance\
paired *t*NMNMInc24 hPGE inc in exp \> cont at 24 h, 48 hNMIL-1β inc in exp \> cont at 1 h, 24 hPGE inc at 24 h \> BS, 168 hIL-1β inc at 24 h \> bas, 48 h, 168 h43IL-1β, TNF-α, NOFriedman, Wilcoxon test Spearman Rank Correl Analy.YNMInc6 mPI, GI, PD inc at 1 m \> BS, 6 m \> BSNMIL-1β inc at 6 m \> bas44RANKL, OPGRepeated measures ANOVANMNMInc48 hPM retr −3.73 ± 1.08 mm (laser grp) and 2.71 ± 0.9 mm (Cont grp) Max mean retr v(t) btw 0 and 48 h. Pain intensity pk at 48 h.NMRANKL - inc at 48 h \> basRANKL/OPG - inc at 48 h \> bas45RANKL, HSP70,ANOVA *post hoc* Fisher's LSDYNMInc24 hAmylase activity in saliva inc at 24 h at exp \> contNMRANKL inc in 24 h \> cont46MMP-8, IL-1βPaired-sample *t*NMNMInc3 mNMMMP-8 dec at 24 h, inc at 3 mIL-1β inc at 3 m47GM-CSF, IF-γ, IL-1β, IL-2, IL-4, IL-5, IL-6, IL-8, IL-10 and TNFα, MMP-9, TIMP-1 and 2, RANKL, OPGPaired non-parametric Kruskall-Wallis. Spearman Rank Sum analy.YNMInc4 h+ve corr of GCF vol and plaque index at 0 at(t), (comp)+ve corr of TNF-α, IL-1β, IL-8, GM-CSF MMP-9 and TIMP levels to speed of OTM at 4 h in Exp corr of IL-1β, IL-8, TNF-α inc to plaque-induced inflam at 0 at (comp).Exp - IL-1β, IL-8, TNFα inc from 4 h to 42 d. RANKL - inc after 42 dExp - TIMP 1 and 2 inc at 4 h, 7 d and 42 d, MMP-9 inc at 4 h, 7 d.Compr-MMP −9 inc at 4 h and 7 d. TIMP-1 inc at 4 h and TIMP-2 at 7 d.Exp \> cont: MMP-9 inc at 0, 4 h at compr, TIMP-2 inc at 0 at Exp, compr48RANK, OPG, OPN, TGF-β1Friedman Dunn's multiple comparisons as *post hoc*YNMInc7 dNMNMRANK - inc in 7 d in exp, compres \> cont OPG - cont \> compres site at 24 h. TGF-β - inc in compres \> cont at 7 d.49MMP-3, MMP-9, MMP-13, MIP-1β, MCP-1, RANTESFriedman, Mann-WhitneyYNMNMNMMMPs inc at 1 h, dec at 24 h. GCF vol at (comp) \> (t) at 21 dNMNM50IL-1β, SP, PGE2SPSS 13.0 paired *t*-test Wilcoxon paired signed rankNMNMInc1 dExp \> Cont:NMExp \> Cont:At D, SP inc at 1 d, 7 dAt M, IL-1β inc at 1 min, 1 h, 1 d, 7 d.At D, PGE2 inc at 1 min, 1 h, 1 d, 7 d.At D, IL-1β at 1 h, 1 d, 7 d.At M, PGE2, SP, inc at 1 min, 1 h, 1 d, 7 d \> BS.Exp \> bas: At M, IL-1β inc at 1 min, 1 h, 1 d, 7 d. At D, IL-1β incAt D, SP, PGE2 inc at 1 d, 7 d \> BS.at 1 h, 1 d, 7 d.51IL-1βWilcoxon signed-rank Mann-Whitney UNMNMInc24 hIL-1β at 24 h, 48 h at exp \> implantNMIL-1β inc at 24, 48 h \> bas IL-1β dec after 24 h, at 48 h, 168 h, 14 d, 21 d.52IL-2, IL-6, IL-81-way ANOVA ( interG) Dunnett's *t* Tukey'sNMNMInc24 hIL-8 inc at 24 h, 48 h in MS grpNMIL-2 inc at 24 h \> basIL-6 inc at 3 m in MS grpIL-8 inc in Exp at 1 h, 24 h, 48 h53CCL-2 (MCP1), CCL-3, CCL-5 (RANTES), IL-8 (CXCL8), IL-1α, IL-1β, IL-6, TNF-αANOVA Tukey's *post hoc* paired and unpaired *t*YNMInc24 hMOPs inc the rate of C retr by 2.3-fold compd to cont and contr C - VAS sign at 24 h for Exp and ConMOPs sign inc cyt and chemokine expressionAll cyt and chemo inc in both Cont and Exp at 24 h IL-1 inc also at 28 d54TNF-αPaired *t* (intra G)\
1-way ANOVA (interG) Dunnett's *t* Tukey'sNMNMInc24 hNMNMTNF-α inc at 24 h55TNF-α, IL-1β, IL-81-way ANOVA Paired student tNMNMTNF-α, IL-1β, IL-8 inc in 1 to 2 d of level1 dGCF vol inc in 1 to 3 d of levelingNMTNF-α, IL-1β, IL-8 inc in 1 to 2 d of level56IL-1β, IL-1RA, AILeast square Regression Pearson product-moment Correl coefficientNMNMAI = 1, then v(t) is not zeroNMC retr at day 84 for 13, 26, 52 kPa were 4.14 ± 0.19, 6.36 ± 1.32, 5.66 ± 1.38 mm respv(t) affected by AI in GCF, stress and IL-1 gene clusterFaster v(t) seen in 26 kPa, higher GCF and allele 1 homozygosity57RANKL, OPG, IL-1, IL-1RA, MMP-9Repeated measures modelsYNMIL-1/IL-1 + IL-1RA - dec\
RANKL/RANKL + OPG - incA - 6 wkNMNMIL-1RA in adults exp \> cont at 3 wk. Dec\
in ratio of (IL-1/\[IL-1 + IL-1RA\]). Inc in\
ratio of RANKL to OPG (RANKL/\[RANKL + OPG\]). RANKL to OPG inc at 6 wk in ado, at 3 wk in A, OPG in ado at Exp \< cont at 6 wkAdo - 3 wk58IL-2, IL-4, IL-6, IL-8, IL-10, GM-CSF, IFN-γ, TNF-α, MCP-1, IP-10Stepwise regressionNMNMNMNMNMIL-6 levels at bas predictive of GCF flows after 1 y of ortho t/tNo sign change59OPG, RANKL2-way ANOVA.\
A Bonferroni fNMNMOPG inc in M, dec in D at 1 h1 hNMNMOPG inc on M, dec in D at 1 h*Ref No.* reference number, *Stats* statistically, *analy* analysis, *appld* applied, *Confd* confounders, *reg* regulation, *Pk* peak, *Sec* secondary, *outcm* outcome, *correl* correlation, *sign* significant, *Y* yes, *N* no, *NM* not mentioned, *inc* increase, *dec* decrease, *fluct* fluctuated, *h* hour, *m* month, *tot* total, *prot* protein, *conc* concentration, *mg* milligram, *ml* milliliter, *g* gram, \> greater than, \< less than, *VAS* visual analog scale, *C* canine, *mov* movement, *b/w* between, *CF* continuous force, *IF* interrupted force, *and* and, *F* force, *Assoc* associated, *gen* genetic, *GCF* gingival crevicular fluid, *compd* compared, *bas* baseline, *IL* interleukin, *βG* beta glucoronidase, *TNF-α* tumor necrosis factor alpha, *SD* short duration, *LD* long duration, *Diff* difference, *vol* volume, *retr* retraction, *correl* correlation, *inflam* inflammation, *Avg* average, *cyt* cytokine, *chemo* chemokine, *knwn* known, *MOPs* micro-osteoperforations, *PI* plaque index, *BOP* bleeding on probing, *exp* experimental, *cont* control, *Exp* experimental tooth, *ant* antagonistic, *Avg* average, *Mx* maxilla, *contr* contralateral, *differen* differentiation, *sepr* separator, *grp* group, *compres* compression, *kPa* kilopascal, *max* maximum, *grw* growth, *T* tooth, *Oc* osteoclast, *RDG* rapid canine distalization group, *HG* hybrid reactor group. *v(t)* velocity of tooth movement, *M* mesial, *D* distal, *level* leveling, *retr* retraction.*CSFs* colony-stimulating factors, *IFNs* interferons, *MCSF* macrophage colony-stimulating factor, *SP* substance P, *IL-1β* interleukin-1 beta, *TNF-α* tumor necrosis factor-alpha, *TGF β* transforming growth factor-beta, *OPG* osteoprotegerin, *OPN* osteopontin, *RANKL* receptor activator of nuclear factor kappa-B ligand, *RANK* receptor activator of nuclear factor kappa-B, *GM-CSF* granulocyte-macrophage colony-stimulating factor, *βG* beta glucuronidase, *PGE2* prostaglandin E2, *IL-1RA* interleukin receptor antagonist, *MCP* monocyte chemoattractant protein, *MMP* matrix metalloproteinases, *MIP* macrophage inflammatory protein, *TIMP* tissue inhibitor of metalloproeintases, *HSP* heat shock proteins, *NO* nitric oxide, *AI* activity index.Figure 1**Flowchart depicting the retrieval of studies for review process.**

The inclusion and exclusion criterion were as under.Inclusion Criteria:Participants/population -Human studies, age groups (if specified), male to female ratio (if specified), controls (either internal where baseline levels are taken as control or external where contralateral or antagonistic tooth is taken as control), sample size \>5 (refers to sample size not number of teeth studied).Intervention(s), exposure(s)-Studies on cytokines \[including interleukins (ILs), tumor necrosis factor (TNF) and growth factors (GFs), colony-stimulating factors (CSFs), interferons (IFNs)\], chemokines, receptors and their antagonists (RANK, RANKL, OPG, OPN) with specified orthodontic mechanics, proper oral hygiene control, no use of antibiotic/anti-inflammatory drugs before or during orthodontic force application, GCF sample collection via periopaper or micropipette placed in sulcus.Exclusion criteriaParticipants/population- In vitro studies, animal studies, sample size \<5, no control. Intervention(s), exposure(s)- Studies on mediators other than cytokines or chemokines or receptors, cytokine or chemokine or receptor measurement in periodontal tissue and not GCF, cytokine or chemokine or receptor levels consequent to periodontal inflammation and not orthodontic force application, cytokine levels measured in peri-implant fluid.

This is a followed data extraction by two reviewers (PK and NM). The data was recorded in a tabular form based on the following criteria:Participant characteristics (Table [1](#Tab1){ref-type="table"}): number of study subjects (not the number of teeth), teeth considered for study (if specified), sites (if mentioned), age of study subjects (either range or mean age ± standard deviation (SD)), sex, controls, and studied mediators. Apart from these, following inclusion criteria were also considered (if mentioned) no history of drug intake, no bone loss, no gingival inflammation, and pocket depth \<2 mm.Study characteristics (Table [2](#Tab2){ref-type="table"}): these were nature of applied force, force magnitudes, force reactivations (if studied), total study duration, observation intervals, and type of tooth movement.Oral hygiene regimen and assessment of gingival health (Table [3](#Tab3){ref-type="table"}): recommendation and frequency of mouthwash intake, oral prophylaxis schedule, use of indices for gingival and periodontal assessment, and their frequency.GCF characteristics (Table [4](#Tab4){ref-type="table"}): time, room temperature and humidity during GCF collection, site, method of collection of GCF, storage and handling characteristics, and technique of mediator analysis.

Quality assessment of the articles included in the review was done based on a Quality Assessment Instrument (QAI) modified and developed from relevant articles in literature \[[@CR20],[@CR21]\] given in Additional file [2](#MOESM2){ref-type="media"}: Annexure 2.

Thirty stringent criteria for evaluation of quality included relevant study design (N = 19), study measurements (N = 3), statistical analysis (N = 5), study results, and conclusions (N = 3). (Additional file [2](#MOESM2){ref-type="media"}: Annexure 2). For objective assessment of quality determination, a scoring system was incorporated where scores of 1 to 10 were considered minimal, 10 to 20 were considered moderate, and 20 to 30 were considered highly sensitive. QAI revealed 26 moderately sensitive and 13 highly sensitive studies. None of the studies fell in the score of 1 to 10.

The results were compiled after grouping of observations from similar studies to arrive at conclusions with relevant clinical implications.

Results {#Sec4}
=======

Thirty-nine shortlisted studies \[[@CR19],[@CR22]-[@CR59]\] were scrutinized for inclusion and exclusion criteria. Two studies that evaluated mediators both in peri-implant crevicular fluid (PMICF) as well as GCF were included \[[@CR51],[@CR54]\] but one study that evaluated the levels of mediators directly in sulcus and not GCF was excluded \[[@CR60]\].

The studies were categorized based on participant characteristics (Table [1](#Tab1){ref-type="table"}), study characteristics (Table [2](#Tab2){ref-type="table"}), oral hygiene regimen and assessment of gingival health (Table [3](#Tab3){ref-type="table"}), and GCF characteristics (Table [4](#Tab4){ref-type="table"}). All studies displayed control, either internal/external. The levels of biomarkers assessed at baseline level (0 day) were taken as control in the former while in the later, contralateral or antagonistic teeth were taken as control. GCF sampling was done with either using periopaper or micropipette that were placed in the gingival sulcus. An overview of the results obtained has been summarized in Table [5](#Tab5){ref-type="table"}.

Sample characteristics {#Sec5}
----------------------

### Sample size {#Sec6}

Of the 39 studies, the sample size varied, smallest being 7 subjects \[[@CR40]\] to a maximum of 84 subjects \[[@CR38]\]. The studies were categorized in four groups, with sample size up to 10 (N = 15), 11 to 20 (N = 16), 21 to 30 (N = 5), and 31 and above (N = 3). Average sample size taken was 10 subjects (N = 10).

Sex predilection {#Sec7}
----------------

Information on sex of the subjects was mentioned in N = 36 studies. One study (N = 1) included only male subjects. Equal numbers of male and female subjects constituted the sample in ten studies (N = 10).

Age distribution {#Sec8}
----------------

Age was expressed as either range or as mean with standard deviation. There was no mention of age in one (N = 1) study. Comparative evaluation of juvenile and adults was reported in two studies (N = 2) and adolescent vs. adults in one study (N = 1). Age groups of male and females subjects were managed separately in three studies (N = 3). Age group of up to 15 years was considered in 19 (N = 19) studies and 15 years and above was considered in 20 (N = 20) studies. One study (N = 1) considered a large age group interval of 18 to 45 years \[[@CR53]\].

Mediators of orthodontic tooth movement {#Sec9}
---------------------------------------

Cytokines, receptors and their antagonists included in the review have been listed in Table [1](#Tab1){ref-type="table"}. The cytokines have been studied singularly or in combination with other mediators. The most often studied cytokine~~s~~ in tooth movement are IL-1β (N = 21), TNF-α (N = 10), IL-8 (N = 8), IL-6 (N = 8), IL-2 (N=4), IL-4, IL-10 (N = 2), IL-1, IL-5, IL-1α (N = 1), OPN (N = 1), and RANKL (N = 7).

Receptors and their antagonists have been studied in the frequency of OPG (N = 8), IL 1RA (N = 5), and RANK (N = 1). Chemokines have been studied in the order of monocyte chemoattractant protein (MCP)-1 (N = 3), RANTES (N = 2), and IP-10 (N = 1). Studies related to growth factors were GMCSF (N = 3), TGF-β (N = 2), and IFN-γ (N = 2) and there was only one (N = 1) study on Leptin.

Time period and observation intervals {#Sec10}
-------------------------------------

The total time duration for studies exhibited large variation from as low as 24 h to as high as 70 weeks. Studies were performed for a duration of 24 h (N = 3), 1 week (N = 10), 2 weeks (N = 2), 3 weeks (N = 2), approximately 1 month (N = 5), 2 months (N = 1), approximately 3 months (N = 10), 4 months (N = 2), 5 months (N = 1), and 6 months and above (N = 4).

GCF collection was done at multiple observation times ranging from a maximum of 11 times (N = 2) to minimum at 2 times (N = 4). Nine studies (N = 9) used 4 observation times; eight (N = 8) studies used 6 observation times; four (N = 4) studies used 2, 5, and 7 observation times; three (N = 3) studies used 3, 9, and 10 observation times; and two (N = 2) studies used 8 observation times.

Thirty-seven (N = 37) studies took observation point before activation as 'zero' or baseline. The protocol followed for GCF collection was 0, 1 h, 24 h, and 7 days (N = 14) and of 0, 1 h, and 24 h (N = 15). An additional observation point at 14 days (N = 7) and 21 days (N = 6) was also considered. An internal control (baseline levels) was considered in N = 12 studies while other studies (N = 27) took an external control that was either contralateral or antagonistic tooth or tooth other than experimental tooth.

Study design {#Sec11}
------------

### Mechanics of force application {#Sec12}

Twenty-seven studies considered retraction of canine (N = 27) which included NiTi coil spring (N = 18), vertical loop (N = 5), screw-based retractors (N = 3), and segmental mechanics (N = 14). Other methods of force applications were separators (N = 4), expansion with hyrax screw (N = 2), labial tipping with offsets in wire (N = 2), bracket placement (N = 1), and leveling of arches (N = 5).

### Type of force application {#Sec13}

Twenty-six studies (N = 26) used continuous force and 12 (N = 12) employed interrupted force. There was no mention of type of force in two (N = 2) studies. Four studies used continuous and interrupted force on different index teeth (N = 4).

### Levels of force {#Sec14}

Twenty-eight studies (N = 28) mentioned levels of force applied while eleven studies (N = 11) have no mention of it. One-hundred fifty-gram force was used in eight studies (N = 8), followed by 250 g (N = 5) and 100 g (N = 4). One study (N = 1) each employed 50, 120, 130, and 200 g; 70 cN; and 2 to 2.5 N of force. A range of force was applied from 4 to 13 kPa (N = 1), 90 to 115 g (N = 1), and 4, 13, 26, 52, or 78 kPa in N = 2 studies. Force reactivation was considered in three (N = 3) studies to compare continuous and interrupted force.

### Oral hygiene regimen and gingival health assessment {#Sec15}

Professional oral prophylaxis was performed before treatment (N = 28) and at every observation point (N = 23) but was not mentioned in the remaining studies. Oral hygiene regimen with recommendation of chlorhexidine mouthwash was mentioned in 11 studies (N = 11) and its frequency (N = 10) studies. Indices for assessment of gingival and periodontal health were employed before the treatment (N = 30) and at every observation point in N = 24 studies.

### *GCF characteristics* {#Sec16}

The GCF samples were collected at a particular time of the day (N = 11), preferably 9 AM to 12 PM and early morning (N = 2). Twenty-eight (N = 28) studies had no mention of time for GCF collection. The room temperature conditions were considered in six (N = 6) studies and humidity in five (N = 5) studies.

The sites for GCF sample collection were either mesial (N = 5) or distal (N = 21) or both mesial and distal (N = 12). GCF collection was done by periopaper (N = 33) studies, filter paper (N = 3), or filter membrane (N = 2). One study (N = 1) did not mention the technique by which GCF was collected.

Depth of insertion of paper for GCF collection was mentioned in 27 studies with the most common practice being a 1-mm depth (N = 26). One study used 2-mm depth of insertion. Duration of GCF collection was specified to be 30 s in most studies (N = 29) followed by 60 s (N = 4), 3 min (N = 1), 10 s (N = 1), and 20 s (N = 1). Repeated measurements were considered in 19 studies (N = 19) with collection repeated once in N = 11 studies, twice in N = 5 studies, and 3 times in N = 3 studies. The interval was 60 s (N = 14), 90 s (N = 1), and 120 s (N = 1).

The samples were stored at −20°C (N = 7), −30°C (N = 6), −70°C (N = 10), and −80°C (N = 9). The GCF from periopaper was retrieved by Periotron (PT)8000 (N = 18), PT6000 (N = 5), PT (N = 2), or electronic scale (N = 3) and was not mentioned in some studies (N = 11). Mediators were analyzed by ELISA (N = 27), immunoassay (IA) (N = 8), Luminex multianalyte technology (LMAT) (N = 1), Bio-Plex human cytokine assay (BHCA) (N = 1), custom protein array (CPA) (N = 1), or Quantibody Ar kit (QAK) (N = 1). Protein concentration in GCF was measured in pg/μl (N = 12), pg (N = 5), pg/mg (N = 1), pg/ml (N = 5), pg/mg (N = 1), pg/μg (N = 30), pg/30 s (N = 2), pg/20 s (N = 1), and pg/site (N = 1) and was not mentioned in N = 3 studies.

The total number of studies included in this review are 39. However in the result section, some of the variables showing number of studies may be more than 39, as few parameters have been divided into subgroups that have been considered as a separate variable.

### Mediator levels in GCF {#Sec17}

#### Interleukins {#d30e9019}

Twenty-one studies on IL-1β were evaluated. Of these, ten studies (N = 10) reported that the peak levels of IL-1β were attained at 24 h \[[@CR19],[@CR22],[@CR27],[@CR33],[@CR37],[@CR42],[@CR50],[@CR51],[@CR53],[@CR54]\]. The peak levels in other studies have also been reported at 4 h \[[@CR47]\], 3 days \[[@CR35],[@CR40]\], 7 days, 21 days \[[@CR29]\], 2 months \[[@CR22]\], around 3 months \[[@CR39],[@CR46]\], and 6 months \[[@CR43]\]. One study mentioned peak for different teeth at different observation points \[[@CR26]\] that resulted in peak for molars at 67 days, for premolars at 32 days and for central incisors at 39 days. Another study did not mention peak but fluctuation in IL-1β levels on application of different stresses of teeth that were correlated with velocity \[[@CR24]\].

One study mentioned IL-1β levels on application of 150-g force to be twice that on application of 50-g force at 24 h and 2 months \[[@CR22]\]. Studies have shown decrease in levels of IL-1β, 14 days after prophylaxis, followed by an increase upon activation of orthodontic appliance (N = 2) \[[@CR26],[@CR39]\]. Forces of short duration show an increase in IL-1β at 7 and 21 days \[[@CR29]\]. Levels of IL-1β in experiment teeth were shown to be greater than control teeth at 1 h \[[@CR19],[@CR33]\], 4 h \[[@CR47]\], 8 h \[[@CR34]\], 24 h \[[@CR19],[@CR33],[@CR34],[@CR42]\],72 h \[[@CR34]\], 7 days \[[@CR33]\], 25 days \[[@CR26],[@CR39]\], 32 days \[[@CR26],[@CR39]\], 33 days \[[@CR39]\], 39 days \[[@CR26],[@CR39]\], 42 days \[[@CR47]\], 46 days \[[@CR26],[@CR39]\], 67 days \[[@CR26],[@CR39]\], and 81 days \[[@CR26],[@CR39]\].

A comparison of continuous and interrupted force was evident in one study \[[@CR37]\] where it was shown that IL-1β levels in continuous force is greater than baseline at 24 h while in interrupted force, levels were greatest at first reactivation.

Difference in IL-1β levels according to site specification was mentioned in one study \[[@CR40]\] where levels at distal site of tooth retraction were greater than mesial site at both 4 and 13 kPa of force application. Placement of elastic separators in molars led to an increase in levels at 1 min, 1 h, 24 h, and 7 days \[[@CR50]\] at mesial site while at distal site, increase was seen at 1 h, 24 h, and 7 days \[[@CR50]\].

An upregulation in IL-1β levels from baseline levels was evident at 1 min \[[@CR50]\], 1 h \[[@CR50]\], 24 h \[[@CR19],[@CR37],[@CR42],[@CR51],[@CR54]\], 48 h \[[@CR51]\], 7 days \[[@CR50]\], 3 months \[[@CR46]\], and 6 months \[[@CR43]\] and downregulation was seen in 48 h, 168 h, 14 days, and 21 days \[[@CR51]\].

For IL-6, the levels were found to increase at 24 h \[[@CR38],[@CR53]\] when continuous forces were applied for retraction or tipping.

IL-8 also increased on application of continuous force for retraction at 1 h \[[@CR36],[@CR52]\] both on tension and pressure sites \[[@CR36]\] and also at 4 h \[[@CR47]\], 24 h, and 48 h \[[@CR52]\]. Placement of separators led to an increase in levels at 24 h \[[@CR27]\]. Fall in levels was observed at 7 days of leveling and an increase was seen at 7 days, 21 days of retraction \[[@CR31]\].

#### TNF-α {#d30e9265}

Application of interrupted force witnessed an increase in levels at 1 h \[[@CR28]\] and 24 h \[[@CR27],[@CR42]\] while continuous force application led to increase in levels at 24 h \[[@CR53],[@CR54]\] or 4 h to 42 days \[[@CR47]\]. There was a decrease in levels in 1 week on continuous force retraction by hybrid retractor (HG) \[[@CR28]\]. TNF-α levels also increased at 1 day \[[@CR54]\], at 3 months \[[@CR29]\] of leveling, and at 6 months, just before retraction \[[@CR29]\]. A comparison of continuous force application by hybrid retractor (HG) by HG to interrupted force by rapid canine distalizer (RDG) showed higher values at 1 h in RDG group compared to HG \[[@CR28]\].

Levels of receptor and their antagonists in GCF {#Sec18}
-----------------------------------------------

### *RANKL* {#Sec19}

RANKL showed an increase in levels at 24 h \[[@CR30],[@CR32],[@CR45]\] greater than control as well as baseline with specific mention of levels in juveniles and adults \[[@CR30],[@CR32]\]. Two studies (N = 2) mentioned increase in levels greater than baseline, one at 48 h \[[@CR44]\] and other at 42 days \[[@CR47]\] at 24 h greater than control \[[@CR45]\], at 48 h \[[@CR44]\], 42 days \[[@CR47]\] greater than baseline. Correlation with age was established with levels in adults being less than juveniles \[[@CR30],[@CR32]\], an increase in RANKL/OPG ratio in 6 weeks in adolescents \[[@CR57]\].

### IL-1RA {#Sec20}

Lower value IL-1RA was shown to be associated with higher velocity of tooth movement (Vt) \[[@CR24]\]. It was also a determinant of activity index (AI) that is ratio of concentrations of IL-1β and IL-1RA in GCF, known to correlate with Vt \[[@CR24],[@CR35],[@CR40],[@CR56]\]. One study mentioned distinction of site where levels at distal site of retraction were greater than mesial and control on application of 4 and 13 kPa force \[[@CR40]\]. A comparison between levels in adults and adolescents revealed a decrease in ratio of IL1/(IL1 + IL-1RA) in 3 weeks \[[@CR57]\].

### *OPG* {#Sec21}

The levels were decreased in experimental teeth at 1 h \[[@CR25]\], 24 h \[[@CR25],[@CR30],[@CR48]\], 168 h \[[@CR25]\], 1 month \[[@CR25]\], and 3 months \[[@CR25]\] than baseline levels. A distinction of age-specified levels of OPG as well as ratio of RANKL/OPG was found to be lower in adults than in juveniles \[[@CR30]\]. The levels of OPG in experimental teeth were found to be lower in adolescents in 6 weeks compared to control teeth \[[@CR57]\]. Its values were less in adolescents in 6 weeks \[[@CR57]\]. Site specification determined levels to increase on tension site (mesial) and to decrease on compression site (distal) \[[@CR59]\].

*Chemokines* \[CCL-2 (MCP1), CCL-3, CCL-5 (RANTES), IL-8 (CXCL8)\] showed an increase in both experimental and control teeth at 24 h of force application \[[@CR53]\]. Levels of IL-8 were increased when force was applied for a short duration in separator placement \[[@CR27]\], or longer duration in initial alignment \[[@CR27]\], 1 to 2 days of leveling \[[@CR54]\], increase from 4 h to 42 days \[[@CR47]\], at 1 h, 24 h, and 48 h \[[@CR52]\] when continuous forces were applied for retraction. Levels also showed a decrease in 7 days of leveling \[[@CR31]\]. A difference in levels was observed with distinction of site, with levels increased at both mesial and distal sites at 1 h of force application, between 24 h and 6 days at tension site and a statistically significant increase at tension site greater than compression site \[[@CR36]\]. Two studies (N = 2) on chemokines did not reveal any significant findings \[[@CR49],[@CR58]\].

Discussion {#Sec22}
==========

This systematic review was primarily aimed to conjure substantial evidence regarding the cytokine, chemokine, receptor and their antagonist (RANK, RANKL, OPG) levels in GCF consequent to application of orthodontic force. The literature revealed heterogeneity in study designs pertaining to participant characteristics, force application, levels of force, GCF collection methods and collection protocol, storage, and oral hygiene maintenance regimen. To draw logical conclusions each of the variables was tabulated and analyzed separately. Associations of change in levels of mediators were established with mechanics of applied orthodontic force, amount of force, force reactivations, differentiation in levels between tension and compression sites, age groups (juveniles and adults, growers and non-growers), and velocity of tooth movement (Vt).

The altering levels, rise, and fall of the mediators in GCF are suggestive of underlying intricate biological remodeling processes in bone and periodontal tissues that eventually leads to OTM. The forces employed for OTM or midpalatal expansion led to an initial increase in levels of bone-resorptive mediators as well as associated receptors namely IL-1β, IL-8, RANKL, and TNF-α as early as 1 min \[[@CR50]\] or 1 h \[[@CR28]\] and attained peak in 24 h \[[@CR19],[@CR22],[@CR27],[@CR30]-[@CR33],[@CR37],[@CR42],[@CR45],[@CR50],[@CR51],[@CR53],[@CR54]\]. These mediators slowly decrease to baseline in subsequent observation points at 48 h, 168 h, 14 days, and 21 days \[[@CR28],[@CR31],[@CR51]\]. On the contrary, bone-forming mediators like OPG show an immediate decrease in levels on application of orthodontic forces at 1 h on distal site of retraction \[[@CR25],[@CR59]\], at 24 h \[[@CR25],[@CR30],[@CR32],[@CR48]\]. The role of RANK, RANKL, and OPG system in governing osteoclastogenesis has also been corroborated in animal studies \[[@CR61],[@CR62]\] and *in vitro* studies \[[@CR63]-[@CR66]\] on periodontal ligament cells. When compressive orthodontic force is applied, upregulation of RANKL occurs which leads to stimulation of PGE2 pathway and finally, osteoclastic activity is initiated which results in bone resorption \[[@CR65],[@CR66]\]. OPG, a RANKL decoy receptor generated by osteoblastic cells and cells of the periodontal ligament, binds to RANKL and inhibits RANK/RANKL interaction that is the mainstay of osteoclastogenesis \[[@CR67]\].

Besides these receptors, other factors that are directly or indirectly responsible for differentiation, survival, and activity of osteoclasts are cytokines (IL-1β, TNFα, IL-6) and chemokines (CCL2, CCL3, CCL5, CCL7, CCL9, IL-8) \[[@CR68],[@CR69]\]. The literature search in the present review found an increase in levels of these mediators in GCF on orthodontic force application. Evidence proves that mechanical stress induces acute inflammatory changes that alter the microvascular environment, with studies supporting local release of mediators IL-1β, TNF-α, and expression of chemokines that ultimately promotes leukocyte adhesion and migration \[[@CR70]\]. IL-1β (N = 21) and TNF-α (N = 10) are the most researched cytokines, supporting their role in the inflammatory changes associated with orthodontic tooth movement (OTM). Variation in mediator levels with type of force and force reactivations has also been evaluated to study their clinical implications with IL-1β, PGE2, or TNF-α levels showing an initial increase, both in continuous and interrupted force \[[@CR28],[@CR37]\]. However, timely reactivations in interrupted force led to an upregulation of these mediators, indicative of greater inflammation than on continuous force application \[[@CR28],[@CR37]\]. This finding is in accordance with other studies that support association of light continuous forces for OTM with minimal inflammation, root resorption, and hyalinization of the periodontal ligament \[[@CR71]-[@CR73]\]. More recent techniques for accelerated orthodontics like micro-osteoperforations have also conducted studies at cellular level that led to increase in GCF levels of cytokines ( IL-1α, IL-1β, IL-6, TNF-α) and chemokines at 24 h, giving evidence of underlying inflammatory process associated with inducing perforations in cortical bone \[[@CR53]\]. An animal study further supports the release of proinflammatory cytokines with micro-osteoperforations, known to recruit osteoclast precursors and hence increase OTM by influencing the bone remodeling process \[[@CR74]\].

Results of the review showed that compression side witnessed a decrease in bone-formative OPG by 24 h \[[@CR48]\] and increase in bone-resorptive RANK and TGF-β1 after 7 days \[[@CR32],[@CR48]\]. Other mediators showing temporal variation on compression side were IL-1β that increased as early as 1 min \[[@CR50]\] or after 4 h \[[@CR47]\], RANKL after 42 days \[[@CR47]\] or after 24 h both in juveniles and adults \[[@CR30]\], and IL-8 after 4 h \[[@CR47]\] or after 10 days \[[@CR36]\]. In contrast, the tension site showed an appreciable increase in TNF-α \[[@CR47]\] and other bone-resorbing mediators like IL-1β, PGE2, and IL-8. But the rise occurred earlier than compression and at all observation points with levels higher than at the compression site \[[@CR36],[@CR47]\]. This difference is hard to understand as the concept of compression on one side and tension on the other side of the tooth undergoing movement is hypothetical. It has been logically contradicted since the anatomical shape and surface morphology of the tooth root cannot be considered confined to definite geometry. Thus, forces when applied lead to biological response in whole of the periodontal apparatus that cannot be differentiated for release of inflammatory mediators in GCF which is a freely circulating fluid in gingival sulcus. Therefore, mediator levels in GCF collected from mesial or distal sites of the tooth may not be indicative solely of compression or tension zone activity.

Synopsis of the studies included in the review also revealed that age and growth status were factors influencing the level of cytokines in GCF that is shown to have an effect on the rate and amount of tooth movement. Mediator levels were seen to vary with growth status of individuals as evaluated in adolescents and adults \[[@CR57]\] or compared in juveniles and adults \[[@CR30],[@CR38]\]. In one study, different mediators were found to increase in different age groups with IL-6, GM-CSF increasing only in juveniles while PGE2 increasing both in juveniles and adults \[[@CR38]\]. In addition, activity index (AI) that is the ratio of IL-1β/IL-1RA in GCF, was found to influence velocity (Vt) of OTM both in growers and non-growers \[[@CR35]\]. Mean Vt of growers was 0.050 mm/day and of non-growers was 0.024 mm/day for the same amount of applied stress that was correlated with higher levels of IL-1β and an increased AI in growers \[[@CR35]\]. A greater Vt and amount of OTM in juveniles as compared to adults could be explained on the basis of a higher RANKL/OPG ratio in GCF in juveniles \[[@CR30]\]. Other studies also support the variation in Vt according to varying mediator levels and AI in GCF \[[@CR24],[@CR35],[@CR40],[@CR56]\]. It was found that association between AI and Vt was stronger from distal than from mesial of retracted teeth, thus emphasizing greater values of IL-1β on the distal \[[@CR40]\]. Thus, evidence from this literature review emphasizes the role of RANKL/OPG ratio in OTM in either of the age groups owing to its significance in osteoclastogenesis and bone resorption that ultimately alters the amount and velocity of OTM.

Secondary outcome of this review was the association of intensity of pain with different force levels. The level of IL-1β was seen to increase at 1 day \[[@CR50]\] that correlated with increased pain intensity and subsequently, there was a decrease seen in 7 days. Another study suggested pain was less with 50-g force as compared to 150-g force that was correlated with greater levels of IL-1β with application of 150-g force \[[@CR22]\]. It can be concluded that 150-g force is marked by higher levels of IL-1β in GCF compared to 50-g force and high pain intensity.

Conclusions {#Sec23}
===========

This systematic review is focused on association of cytokine and receptor levels or activity index in GCF with velocity of tooth movement, nature of force applied, pain intensity, and growth status/age of the subjects, leading to following conclusions:Application of orthodontic forces causes an immediate release of inflammatory bone-resorptive mediators (IL-1β, TNF-α) in 1 h that reach peak in 24 h, thus supporting the role of inflammation in initial OTM.Bone-forming mediators like OPG witnessed a fall in levels immediately after orthodontic force application indicating bone resorption to be the key process in initiating tooth movement.The levels of cytokines decrease after attaining peak values, mostly at 24 h in continuous forces but repeated activations in interrupted force upregulate their secretion.A rise in GCF levels of IL-1β with higher force levels (150 vs 50 g) has been linked to increased pain intensity during OTM.Juveniles exhibiting greater RANKL/OPG ratio and activity index (AI) (IL-1β/IL-1RA) in GCF displayed faster rate of OTM than adults or non-growers.Increased velocity of tooth movement (Vt) has been correlated with a greater activity index (AI) in GCF.

The literature search and critical review have also provided a lead to lacunae of the research in this field. There is lack of uniformity of study design with respect to sample size, age, sex ratio, observation intervals, duration of observations, mechanism employed to initiate OTM and ethnic/nutritional barriers. These are potential confounders which can influence the outcome \[[@CR75]\]. A major drawback identified in the current review was the lack of consideration of sex on mediator levels that are known to be sensitive to estrous cycle. Animal studies have evaluated correlation between ovarian activity and PGE2, IL-1β levels in GCF of female cats during OTM. Results revealed that mediator levels of estrous groups were lower than anestrous and ovariectomized groups on 6 and 12 days, indicating that ovarian activity can affect OTM \[[@CR76]\]. The threshold levels of the inflammatory mediators for initiation for OTM also remain unexplored. Besides GCF, peri-implant fluid may also be a potential medium to study these markers noninvasively in future studies \[[@CR77]\]. Search of pain killers having least effect on bone-resorbing mediator levels as a drug of choice may be a potential area of future research \[[@CR78]\]. Research related to the role of mediators in external apical root resorption (EARR) and relapse has also received little attention and are important research areas requiring further exploration.
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